A Review on Next Generation eCTD – eCTD v4.0
Abstract
eCTD 4.0 is the first major upgrade of eCTD in over a decade, designed to meet the objective of using a single electronic message standard for exchange of regulatory information through internationally approved standards. It is based on the Health Level Seven (HL7) Standard called Regulatory Product Submissions (RPS). HL7 is an ISO-certified standards body that builds health standards, specifically for North America but has been adopted worldwide. With RPS, the regulatory information is transferred in the form of an xml message that is represented by the colour coded R-MIM (Refined Message Information Model) diagram which efficiently describes each content of the regulatory data to be processed and exchanged between sponsors and regulatory authorities. The International Council on Harmonisation (ICH) has adopted the RPS standard as basis for eCTD version 4.0, and implementation guides for this format have been issued by ICH, US FDA, Health Canada, Japan PMDA, and EU EMA. ICH has built requirements into RPS that significantly enhances the regulatory submission and review process for sponsors and regulatory officials in the eCTD v4.0 version. This review provides a brief outlook on the new eCTD v4.0 standard.
Downloads
References
https://admin.ich.org/sites/default/files/inline-files/eCTDv4_0_SupportDocumentation_v1_3.pdf
2. Orientation Material for M8: eCTD EWG eCTD v4.0 Implementation Package v1.5 [Internet]. ICH;2022 May [cited 2023 Jun 01]. Available from:
https://admin.ich.org/sites/default/files/inline-files/eCTDv4_0_Orientation_Material_v1_5.pdf
3. A Considered Review of the Practicalities of Implementing eCTD 4.0 [Internet]. Calyx;2022 Jun 06 [cited 2023 Jun 22].Available from:
https://www.calyx.ai/journal/a-considered-review-of-the-practicalities-of-implementing-ectd-4
4. eCTD 4.0: Key Changes & Impact on Submission Content Preparation [Internet]. Linkedin;2022 Aug 01 [cited 2023 Oct 06]. Available from:
https://www.linkedin.com/pulse/ectd-40-key-changes-impact-submission-content-geert-van-peteghem
5. Regulated Product Submission [Internet]. FDA; 2018 Mar 27 [cited 2019 Nov 30]. Available from:
https://www.fda.gov/industry/fda-data-standards-advisory-board/regulated-product-submission
6. ICH electronic Common Technical Document – eCTD 4.0 [Internet]. ICH; 2023 Jan [cited 2023 Mar 17]. Available from:
https://ich.org/page/ich-electronic-common-technical-document-ectd-v40
7. U.S. Department of Health and Human Services ‘Electronic Common Technical Document (eCTD) v4.0 Technical Conformance Guide’ [Internet]. USFDA; 2022 Sep [cited 2023 Apr 03]. Available from:
https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/electronic-common-technical-document-ectd-v40
8. ICH Electronic Common Technical Document (eCTD )v4.0 Implementation Guide v1.5 [Internet]. ICH; 2022 May 24 [cited 2023 Jul 14]. Available from:
https://ich.org/page/ich-electronic-common-technical-document-ectd-v40
9. FDA Module 1 Electronic Common Technical Document (eCTD ) v4.0 Implementation Guide v1.5 [Internet]. USFDA; 2022 Sep [cited 2023 May 10]. Available from:
https://www.fda.gov/drugs/electronic-regulatory-submission-and-review/electronic-common-technical-document-ectd-v40
10. ICH Electronic Common Technical Document (eCTD) v4.0 Implementation Guide in Japan v1.5.0 [Internet]. Japan PMDA;2023 Feb 06 [cited 2023 Apr 19]. Available from:
https://www.pmda.go.jp/int-activities/int-harmony/ich/0119.html
11. Draft Guidance document profile: Canadian Module 1 Technical Implementation Guide for the Electronic Common Technical Document (eCTD) v4.0 Format [Internet]. Health Canada; 2019 Jun 26 [cited 2022 Jul 04]. Available from:
https://www.canada.ca/en/health-canada/services/drugs-health-products/public-involvement-consultations/drug-products/draft-guidance-canadian-module-1-technical-implementation-guide-ectd-v4-format/document.html
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM